111In-pentetreotide scintigraphy in the detection of insulinomas: Importance of SPECT imaging

O. Schillaci, R. Massa, F. Scopinaro

Research output: Contribution to journalArticle

Abstract

The aim of this study was to determine whether the systematic use of SPECT can increase the reported low sensitivity of somatostatin receptor scintigraphy (SRS) in detecting insulinomas. Methods: Fourteen patients were evaluated. After 111Inpentetreotide injection (~250 MBq intravenously), abdominal SPECT images were obtained at 4 h and multiple planar images were obtained at 4 and 24 h. MRI and CT were performed within 1 mo of SRS. Sixteen tumors were histologically verified after surgery in 14 patients. Results: SPECT revealed 14 lesions in 12 patients (sensitivity, 87.5%), both planar SRS and MRI revealed 7 tumors in 7 patients (sensitivity, 43.8%), and CT revealed only 5 lesions in 4 patients (sensitivity, 31.3%). Moreover, in 4 patients SPECT was the only examination with positive findings. Conclusion: SPECT at 4 h is mandatory for preoperative detection of insulinomas using SRS because the images are more sensitive than planar images and are superior to images from other conventional methods.

Original languageEnglish
Pages (from-to)459-462
Number of pages4
JournalJournal of Nuclear Medicine
Volume41
Issue number3
Publication statusPublished - 2000

Fingerprint

Insulinoma
Single-Photon Emission-Computed Tomography
Radionuclide Imaging
Somatostatin Receptors
pentetreotide
Neoplasms
Injections

Keywords

  • Insulinomas
  • Somatostatin receptor scintigraphy
  • SPECT

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology

Cite this

111In-pentetreotide scintigraphy in the detection of insulinomas : Importance of SPECT imaging. / Schillaci, O.; Massa, R.; Scopinaro, F.

In: Journal of Nuclear Medicine, Vol. 41, No. 3, 2000, p. 459-462.

Research output: Contribution to journalArticle

Schillaci, O. ; Massa, R. ; Scopinaro, F. / 111In-pentetreotide scintigraphy in the detection of insulinomas : Importance of SPECT imaging. In: Journal of Nuclear Medicine. 2000 ; Vol. 41, No. 3. pp. 459-462.
@article{b4c360a210474e2c8b720a5df38c1edf,
title = "111In-pentetreotide scintigraphy in the detection of insulinomas: Importance of SPECT imaging",
abstract = "The aim of this study was to determine whether the systematic use of SPECT can increase the reported low sensitivity of somatostatin receptor scintigraphy (SRS) in detecting insulinomas. Methods: Fourteen patients were evaluated. After 111Inpentetreotide injection (~250 MBq intravenously), abdominal SPECT images were obtained at 4 h and multiple planar images were obtained at 4 and 24 h. MRI and CT were performed within 1 mo of SRS. Sixteen tumors were histologically verified after surgery in 14 patients. Results: SPECT revealed 14 lesions in 12 patients (sensitivity, 87.5{\%}), both planar SRS and MRI revealed 7 tumors in 7 patients (sensitivity, 43.8{\%}), and CT revealed only 5 lesions in 4 patients (sensitivity, 31.3{\%}). Moreover, in 4 patients SPECT was the only examination with positive findings. Conclusion: SPECT at 4 h is mandatory for preoperative detection of insulinomas using SRS because the images are more sensitive than planar images and are superior to images from other conventional methods.",
keywords = "Insulinomas, Somatostatin receptor scintigraphy, SPECT",
author = "O. Schillaci and R. Massa and F. Scopinaro",
year = "2000",
language = "English",
volume = "41",
pages = "459--462",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "3",

}

TY - JOUR

T1 - 111In-pentetreotide scintigraphy in the detection of insulinomas

T2 - Importance of SPECT imaging

AU - Schillaci, O.

AU - Massa, R.

AU - Scopinaro, F.

PY - 2000

Y1 - 2000

N2 - The aim of this study was to determine whether the systematic use of SPECT can increase the reported low sensitivity of somatostatin receptor scintigraphy (SRS) in detecting insulinomas. Methods: Fourteen patients were evaluated. After 111Inpentetreotide injection (~250 MBq intravenously), abdominal SPECT images were obtained at 4 h and multiple planar images were obtained at 4 and 24 h. MRI and CT were performed within 1 mo of SRS. Sixteen tumors were histologically verified after surgery in 14 patients. Results: SPECT revealed 14 lesions in 12 patients (sensitivity, 87.5%), both planar SRS and MRI revealed 7 tumors in 7 patients (sensitivity, 43.8%), and CT revealed only 5 lesions in 4 patients (sensitivity, 31.3%). Moreover, in 4 patients SPECT was the only examination with positive findings. Conclusion: SPECT at 4 h is mandatory for preoperative detection of insulinomas using SRS because the images are more sensitive than planar images and are superior to images from other conventional methods.

AB - The aim of this study was to determine whether the systematic use of SPECT can increase the reported low sensitivity of somatostatin receptor scintigraphy (SRS) in detecting insulinomas. Methods: Fourteen patients were evaluated. After 111Inpentetreotide injection (~250 MBq intravenously), abdominal SPECT images were obtained at 4 h and multiple planar images were obtained at 4 and 24 h. MRI and CT were performed within 1 mo of SRS. Sixteen tumors were histologically verified after surgery in 14 patients. Results: SPECT revealed 14 lesions in 12 patients (sensitivity, 87.5%), both planar SRS and MRI revealed 7 tumors in 7 patients (sensitivity, 43.8%), and CT revealed only 5 lesions in 4 patients (sensitivity, 31.3%). Moreover, in 4 patients SPECT was the only examination with positive findings. Conclusion: SPECT at 4 h is mandatory for preoperative detection of insulinomas using SRS because the images are more sensitive than planar images and are superior to images from other conventional methods.

KW - Insulinomas

KW - Somatostatin receptor scintigraphy

KW - SPECT

UR - http://www.scopus.com/inward/record.url?scp=0033622158&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033622158&partnerID=8YFLogxK

M3 - Article

C2 - 10716319

AN - SCOPUS:0033622158

VL - 41

SP - 459

EP - 462

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 3

ER -